English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Our objective was to assess the value of 68 Ga-DOTATOC and carbidopa-assisted 18 F-fluorodihydroxyphenylalanine ( 18 F-DOPA) in 21 hypoglycemic patients. Methods: All patients who underwent 68 Ga-DOTATOC or carbidopa-assisted 18 F-DOPA PET/CT for suspicion of insulinoma from January 2019 to January 2021 were retrospectively analyzed. A final diagnosis of insulinoma was determined by pathologic reports or consensus. Results: During the study period, 21 patients underwent both 68 Ga-DOTATOC and 18 F-DOPA PET/CT. A final diagnosis of insulin-secreting tumor was reached in 12 cases, including 11 insulinomas and 1 small mixed neuroendocrine/nonneuroendocrine neoplasm. 18 F-DOPA and 68 Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 11 cases, respectively, with 4 concordant positive findings. Moreover, 1 insulinoma was visualized exclusively by 18 F-DOPA PET/CT and 3 by 68 Ga-DOTATOC PET/CT only. 18 F-DOPA and 68 Ga-DOTATOC PET/CT were falsely positive in 1 nonfunctioning pancreatic neuroendocrine tumor. Conclusion: When 68 Ga-exendin-4 is not available, 68 Ga-somatostatin receptor PET/CT should be the first choice for insulinoma functional imaging.

Value of 68Ga-DOTATOC and Carbidopa-Assisted 18F-DOPA PET/CT for Insulinoma Localization

Value of ⁶⁸Ga-DOTATOC and Carbidopa-Assisted ¹⁸F-DOPA PET/CT for Insulinoma Localization